2024-513993-23-00
CTIS ↗
AZACITIDINE
Patients with higher risk myelodysplastic syndrome (MDS) who have not yet been treated for their disease
pharma · Breast Cancer · NSCLC (Advanced Non-small Cell Lung Cancer) · ALXO
ALX ONCOLOGY HOLDINGS
ALX ONCOLOGY HOLDINGS INC
ALX ONCOLOGY HOLDINGS trial registry — 14 ClinicalTrials.gov studies with program phase, status, and indication context.
4545 Horizon Hill Blvd, San Antonio, Texas 78229-2263, US HQ
2015 Founded
2 Employees
Public company Type
ALXO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 4545 Horizon Hill Blvd, San Antonio, Texas 78229-2263, US
- Founded
- 2015
- Employees
- 2
- Programs
- 13
- Drugs
- 16
- Patents
- 0
ALX ONCOLOGY HOLDINGS clinical trials
Registry index of 14 ClinicalTrials.gov studies linked to ALX ONCOLOGY HOLDINGS programs — each row shows trial ID, program name, phase, status, and indication.
ALX ONCOLOGY HOLDINGS trial registry — 14 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for ALX ONCOLOGY HOLDINGS.
-
AT148009 — Phase 2
Clinical update -
Zanidatamab — Phase 2
Clinical update -
AZACITIDINE — Phase 2
Clinical update -
Evorpacept (ALX148) — Phase 3
Clinical update -
Evorpacept (ALX148) — Phase 2
Clinical update -
Evorpacept (ALX148) — Phase 2
Clinical update -
Pembrolizumab — Phase 2
Clinical update -
evorpacept — Phase 2
Clinical update